External radiation exposure to the families living with patients with neuroendocrine tumors receiving 177Lu-DOTATATE radiotherapy

Novartis Pharma K.K.0 个研究点目标入组 30 人开始时间: 2024年12月18日最近更新: 2025年1月30日

试验速览

暂无简介。

•Inclusion criteria for patients:
•Patients with NET receiving 177Lu-DOTATATE therapy at standard dose (7.4 GBq+-10%).
•Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
•Patients must be living with one or more people (e.g., spouse, partner, child, flat mate etc.)
•Patients must give written informed consent form to allow them and their family members to participate in the study.
•Patients must be 18 years of age or older.
•Inclusion criteria for study participants (family members):
•Family members must provide written informed consent form to participate in the study.
•Family members must be living with a patient undergoing 177Lu-DOTATATE radiation therapy.
•Family members must be 18 years of age or older.
•Family members should have normal cognitive function.

•Any patient/family member participating in another clinical trial or study.
•Any patient/family member who is pregnant or lactating.
•Any family member undergoing any radiotherapy or exposure to medical diagnostics.
•Any family member who works in a radiation-related field (e.g.: HCPs, employees in radio pharma companies, etc.).

cumulative external exposure dose

时间窗: 14 days

To evaluate the cumulative external exposure dose of family members living with patients treated with 177Lu-DOTATATE radiotherapy

发起方